TY - JOUR
T1 - Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats
AU - Carter, Lawrence P.
AU - Koek, Wouter
AU - France, Charles P.
PY - 2006/11
Y1 - 2006/11
N2 - Gamma-hydroxybutyrate (GHB) is used therapeutically and recreationally worldwide. Since the scheduling of GHB by the USA and the United Nations in 2000-2001, the recreational use of GHB precursors has reportedly increased. The aim of this study was to examine if potency differences of GHB and GHB-like compounds are due to their blood-brain barrier permeability. The effects of peripheral and central administration of GHB, GHB precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), and the gamma-aminobutyric acid (GABA) B receptor agonist baclofen on schedule-controlled responding were examined in rats. GHB and baclofen were 276- and 253-fold more potent, respectively, after intracerebroventricular (i.c.v.) administration than after intraperitoneal (i.p.) administration, whereas GBL and 1,4-BD, up to a dose of 1780 μg were without effect after i.c.v. administration. These data suggest that GBL and 1,4-BD are not metabolically converted to GHB in the brain, that enhanced brain penetration cannot account for potency differences between compounds, and that baclofen, like GHB, can readily cross the blood-brain barrier.
AB - Gamma-hydroxybutyrate (GHB) is used therapeutically and recreationally worldwide. Since the scheduling of GHB by the USA and the United Nations in 2000-2001, the recreational use of GHB precursors has reportedly increased. The aim of this study was to examine if potency differences of GHB and GHB-like compounds are due to their blood-brain barrier permeability. The effects of peripheral and central administration of GHB, GHB precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD), and the gamma-aminobutyric acid (GABA) B receptor agonist baclofen on schedule-controlled responding were examined in rats. GHB and baclofen were 276- and 253-fold more potent, respectively, after intracerebroventricular (i.c.v.) administration than after intraperitoneal (i.p.) administration, whereas GBL and 1,4-BD, up to a dose of 1780 μg were without effect after i.c.v. administration. These data suggest that GBL and 1,4-BD are not metabolically converted to GHB in the brain, that enhanced brain penetration cannot account for potency differences between compounds, and that baclofen, like GHB, can readily cross the blood-brain barrier.
KW - Baclofen
KW - Central
KW - Operant
KW - Peripheral
KW - Potency
UR - http://www.scopus.com/inward/record.url?scp=33750927653&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750927653&partnerID=8YFLogxK
U2 - 10.1111/j.1460-9568.2006.05146.x
DO - 10.1111/j.1460-9568.2006.05146.x
M3 - Article
C2 - 17100847
AN - SCOPUS:33750927653
SN - 0953-816X
VL - 24
SP - 2595
EP - 2600
JO - European Journal of Neuroscience
JF - European Journal of Neuroscience
IS - 9
ER -